Ranbaxy Laboratories Limited will launch Olvance (Olmesartan Medoxomil, antihypertensive), a drug from Daiichi Sankyo's stable, in the country. The company will promote and market the drug in India.
In a statement issued to Bombay Stock Exchange, Malvinder Singh, chairman, CEO and managing director, Ranbaxy, said, "The launch of Olvance is a historic moment in the collaboration between Ranbaxy and Daiichi Sankyo. This marks the beginning of a productive engagement that will harness the respective strengths of Daiichi Sankyo and Ranbaxy to establish a much stronger platform for Ranbaxy in India.”
Takashi Shoda, President and CEO of Daiichi Sankyo, said, “Olmesartan Medoxomil is a superior antihypertensive medicine. The launch of this product marks our intent to scale up our innovative product introductions in India through Ranbaxy.”
Olvance is an effective, fast acting and well tolerated antihypertensive agent that can be administered, once daily. Olmesartan Medoxomil belongs to the family of Angiotensin II receptor blocker (ARB) class of anti-hypertensives. It is available worldwide in more than 50 countries.
